Sydney graduated with a JD from the University of Denver Sturm College of Law in December 2018. Previously, she graduated magna cum laude from, Colorado State University with a Bachelor's in Business Administration with a concentration in Marketing, a certificate in International Business, and a minor in Political Science. Prior to attending law school she worked in Business and Strategic Planning at Hewlett Packard and worked in the Legal and Regulatory Department at Time Warner Telecom.
In addition to contributing to The Race to the Bottom, Sydney is involved with DU Moot Court competitions. Her legal interests include corporate litigation and compliance, and she is pursuing a certificate in the Corporate and Commercial Law.
Outside of law school, she enjoys camping and hiking with her puppy Ari, cooking, and as a Colorado native she looks forward to rooting for the Broncos and Avalanche on game day.
Connect with Sydney on LinkedIn.
With the popularity and growth of cryptocurrencies many companies are using initial coin offerings (“ICOs”) to raise capital. ICOs allow investors to exchange typical currency for a coin or token. The ICO market continues to grow—in 2017 an estimated $4 billion was raised through ICOs. (Jay Clayton, U.S. Securities and Exchange Commission). So far, 2018 has seen $2 billion raised through ICOs. (David Sacks and Josh Stein, Harbor). Funding a venture through a cryptocurrency gives companies and individuals the ability to make transfers regardless of geographic location, and it has lower transaction costs than traditional financing methods. Using cryptocurrencies, however, also has drawbacks—mainly anonymity of purchasers and sellers coupled with a lack of government regulation.
In Pfizer Inc. 2018 BL 030118 (March 1, 2018), Pfizer Inc. ("Pfizer") asked the staff of the Securities and Exchange Commission (“SEC”) to permit the omission of a shareholder proposal submitted by Trinity Health (“Proponents”) requesting Pfizer disclose the risks from rising pressure to contain U.S. prescription drug prices and explain how Pfizer plans to mitigate those risks. The SEC issued the requested no action letter allowing for the exclusion of the proposal under Rule 14a-8(i)(10).